African Trypanosomiasis - Pipeline Review, H1 2019

Global Markets Direct’s, ‘African Trypanosomiasis - Pipeline Review, H1 2019’, provides an overview of the African Trypanosomiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for African Trypanosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for African Trypanosomiasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of African Trypanosomiasis

- The report reviews pipeline therapeutics for African Trypanosomiasis by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved African Trypanosomiasis therapeutics and enlists all their major and minor projects

- The report assesses African Trypanosomiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for African Trypanosomiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for African Trypanosomiasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding African Trypanosomiasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

F. Hoffmann-La Roche Ltd

Novartis AG

Sanofi

Scynexis Inc

F. Hoffmann-La Roche Ltd

Novartis AG

Sanofi

Scynexis Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

African Trypanosomiasis – Overview

African Trypanosomiasis – Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

African Trypanosomiasis – Overview

African Trypanosomiasis – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

African Trypanosomiasis – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

African Trypanosomiasis – Companies Involved in Therapeutics Development

F. Hoffmann-La Roche Ltd

Novartis AG

Sanofi

Scynexis Inc

African Trypanosomiasis – Drug Profiles

acoziborole – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBL-0137 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DDD-100097 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fexinidazole – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GNF-6702 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MDL-73811 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

melarsoprol hydroxypropylbetadex – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MS-08 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides for Sleeping Sickness – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Infectious Diseases – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Sleeping Sickness – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for African Trypanosomiasis, Chagas Disease and Leishmaniasis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit N-Myristoyltransferase for African Trypanosomiasis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Rhodesain for African Trypanosomiasis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Variant Surface Glycoprotein for African Trypanosomiasis – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

African Trypanosomiasis – Dormant Projects

African Trypanosomiasis – Discontinued Products

African Trypanosomiasis – Product Development Milestones

Featured News & Press Releases

Nov 16, 2018: Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness

Nov 16, 2018: CHMP recommends first oral-only treatment for sleeping sickness

Jan 31, 2018: Sanofi, DNDi seek European Medicines Agency review for sleeping sickness treatment

Nov 04, 2017: Phase II/III Studies Show High Efficacy and Safety of Fexinidazole, the First Oral Treatment for Sleeping Sickness

Aug 30, 2016: UGA researchers discover a drug for a tropical disease

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for African Trypanosomiasis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Tables

Number of Products under Development for African Trypanosomiasis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

African Trypanosomiasis – Pipeline by F. Hoffmann-La Roche Ltd, H1 2019

African Trypanosomiasis – Pipeline by Novartis AG, H1 2019

African Trypanosomiasis – Pipeline by Sanofi, H1 2019

African Trypanosomiasis – Pipeline by Scynexis Inc, H1 2019

African Trypanosomiasis – Dormant Projects, H1 2019

African Trypanosomiasis – Discontinued Products, H1 2019

List of Figures

List of Figures

Number of Products under Development for African Trypanosomiasis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products ...

List of Figures

Number of Products under Development for African Trypanosomiasis, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports